T-like NK cell therapy for cancers with low MHC-I
Part of Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a lab-made immune cell treatment (T-like NK cells) for advanced cancers that have low or missing MHC-I on their cells. Because the treatment aims to “re-activate” the immune system against these cancers, you may be eligible if your cancer matches this feature and you meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that shows low or no MHC-I (a surface marker on cancer cells; low means it may be harder for the immune system to recognize).
- You are expected to live more than 12 weeks.
- Your heart, lungs, liver, and kidneys are healthy enough for treatment (labs/scans must be adequate).
- Your own immune cells are available (the trial needs your T cells for the treatment).
- You (or your guardian) can understand the study and sign an informed consent, and you receive a copy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests an experimental immune cell therapy called iNK for people with advanced solid tumors that no longer respond to standard treatments. The therapy uses natural killer (NK) cells, which are part of your immune system, to target and attack cancer cells. The goal is to see if it is safe and if it can help shrink tumors or slow their growth.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Hear when a new Anti-cancer Cell Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.